Texas

The Orphan Drug Act (ODA) was enacted on January 4, 1983. It was designed to encourage the development of drugs for rare diseases. The law was amended the following year to define rare diseases as ones that affect fewer than 200,000 people in the U.S. But it also included drugs that affect more than 200,000 people the costs of developing and marketing the drug in the U.S. would exceed revenue from U.S. sales.

As a valued member of our BioSpace community, we are eager to hear more from you and other readers in 2019. Let us know which topics you want to hear more about.

For 30 years, BioSpace Hotbed maps have been a guiding light for life science professionals. The original, watercolor artistry of the maps adorn offices around the country and also offer an at-a-glance reference to the industry’s leading innovators and employers.

As 2018 comes to a close, analysts, journalists, investors and industry-watchers are studying their crystal balls to see what trends to watch in the upcoming year. Here are 7 trends most likely to be hitting the news cycle.

Although the size of the IPO is one aspect of determining the success of a company’s public launch, it’s not the only metric. How the stock does in the ensuing months is a very important consideration.

The Boston area, specifically Cambridge, has the highest concentration of biopharma companies in the U.S. That is followed rather closely by the San Francisco Bay Area. Many states want to encourage life science development—the return on investment can be very high, and the jobs they create are often well-paying jobs for skilled workers.

More than 200 children have died this year from influenza and 80 percent were not vaccinated, expert says.

Abeona did not specify the type of misconduct that Carsten Thiel engaged in, but it was serious enough to warrant termination.

Both the Chinese and American researchers involved in using CRISPR-Cas9 gene editing to alter the DNA of embryos for seven couples in China are under investigation. The work has also received near-universal condemnation worldwide.

Although the recent mid-term elections had a historic changeover of control in the House of Representatives from the GOP to the Democrats, at least one change in the U.S. Senate has the biopharma industry on edge. Sen. Chuck Grassley (R-Iowa) will take over as head of the Senate Finance Committee.